Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ConclusionsThe magnitude of the statistically significant (P 
Source: Targeted Oncology - September 3, 2021 Category: Cancer & Oncology Source Type: research

A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab
ConclusionRCC patients with ≥ 1 BM who received I + N therapy had a relatively low response rate, PFS, and OS. Strategies to improve outcomes in this subset of patients are needed. (Source: Targeted Oncology)
Source: Targeted Oncology - August 11, 2021 Category: Cancer & Oncology Source Type: research

Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
AbstractBackgroundPatients with metastatic renal cell carcinoma (mRCC) are often elderly and have various comorbidities, including cardiovascular diseases. Although these patients have extensive co-exposure to targeted therapy and cardiovascular drugs, the impact of this co-exposure on outcomes for patients with mRCC remains unclear.ObjectiveOur objective was to evaluate the association between the use of cardiovascular medication and survival of patients with mRCC.MethodsThe study included 343 consecutive patients with mRCC treated with sunitinib or pazopanib in the first line. Clinical data obtained from the Renal Cell C...
Source: Targeted Oncology - August 7, 2021 Category: Cancer & Oncology Source Type: research

Isatuximab: A Review of Its Use in Multiple Myeloma
AbstractIsatuximab (Sarclisa®; isatuximab-irfc in the USA) is an anti-CD38 monoclonal antibody (mAb) approved for use in the treatment of adults with multiple myeloma (MM): in combination with pomalidomide and dexamethasone for those with relapsed and refractory MM (RRMM) who have received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor; and in combination with carfilzomib and dexamethasone for those with relapsed MM who have received ≥ 1 prior therapy. In phase III studies, the addition of isatuximab to pomalidomide and dexamethasone significantly prolo nged progression-free ...
Source: Targeted Oncology - August 5, 2021 Category: Cancer & Oncology Source Type: research

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
AbstractBackgroundLimited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alone in real-world practice.ObjectiveTo evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2 ‒ MBC) in routine US clinical practice.Patients and MethodsThis retrospective analysis included HR+/HER2 ‒ MBC patients who initiated PAL+LET or LET as first-line treatment between February 2015 and September...
Source: Targeted Oncology - August 2, 2021 Category: Cancer & Oncology Source Type: research

Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
ConclusionsOur data show that cabozantinib is active in pretreated patients with sarcomatoid renal cell carcinoma. Biomarkers are needed in this field to select patients for multi-kinase inhibitors or other options. (Source: Targeted Oncology)
Source: Targeted Oncology - August 2, 2021 Category: Cancer & Oncology Source Type: research

Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation
ConclusionsJAK1i+ ATRA lead to decreases in cell cycle followed by myeloid differentiation and cell death in human leukemias. These findings highlight potential uses of ATRA-based differentiation therapy of non-M3 human leukemia. (Source: Targeted Oncology)
Source: Targeted Oncology - July 29, 2021 Category: Cancer & Oncology Source Type: research

Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
This study evaluated the risk of infection for patients with solid tumors undergoing ICI  therapy based on a systematic review and meta-analysis.Patients and MethodsThe Cochrane Library, EMBASE, and Pubmed databases were searched up to 1 December 2020. Randomized trials comparing any ICI alone, with chemotherapy (CT), or with other agentsversus placebo, CT, or other agents were included. Three independent reviewers extracted the data. The primary outcome was the RR of all-grade (G) and G3 –5 infections for patients receiving ICI-based treatments. Random or fixed-effect models were used according to statistical h...
Source: Targeted Oncology - July 5, 2021 Category: Cancer & Oncology Source Type: research

Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
ConclusionEntinostat with exemestane showed reasonable safety, tolerability, and encouraging efficacy in Chinese patients with HR+/HER2 − MBC. These results support further evaluation in a randomized, double-blind Phase III study with a weekly 5 mg entinostat dose in a Chinese population.Trial RegistrationNCT02833155. (Source: Targeted Oncology)
Source: Targeted Oncology - July 1, 2021 Category: Cancer & Oncology Source Type: research

Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
ConclusionsEarly treatment interruption, which exerted a negative effect for TKIs, was a preferable event for nivolumab plus ipilimumab when considering PFS. Furthermore, early administration of high-dose corticosteroids did not diminish the anti-tumor effect of nivolumab plus ipilimumab. (Source: Targeted Oncology)
Source: Targeted Oncology - June 26, 2021 Category: Cancer & Oncology Source Type: research

Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
AbstractBackgroundFor research with human participants to be ethical, risk must be in a favorable balance with potential benefits. Little is known about the risk/benefit ratio for pediatric cancer phase II trials testing targeted therapies.ObjectiveOur aim was to conduct a systematic review of preliminary efficacy and safety profiles of phase II targeted therapy clinical trials in pediatric oncology.MethodsOur protocol was prospectively registered in PROSPERO (CRD42020146491). We searched EMBASE and PubMed for phase II pediatric cancer trials testing targeted agents. We included solid and hematological malignancy studies p...
Source: Targeted Oncology - June 10, 2021 Category: Cancer & Oncology Source Type: research

Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
AbstractBackgroundB-cell maturation antigen (BCMA) is expressed on malignant plasma cells from patients with multiple myeloma (MM). These patients have higher levels of serum (s)BCMA than healthy subjects, and levels correlate with disease status. The half-life of sBCMA is only 24 –36 h, and levels are independent of renal function.ObjectiveWe determined whether baseline sBCMA values, a ≥ 25% increase, and a ≥ 50% decrease during treatment predicted progression-free survival (PFS) and overall survival (OS) among 81 patients with relapsed/refractory MM (RRMM) starting new treatments.MethodsSerum was obtained on ...
Source: Targeted Oncology - June 7, 2021 Category: Cancer & Oncology Source Type: research

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study
ConclusionsDespite the limitations of a retrospective analysis and the small number of patients, the benefit of adjuvant imatinib 400 mg daily in high-risk patients appeared relevant. Patients with advanced disease receiving imatinib 400 mg with subsequent dose escalation had a TIF similar to that observed with an initial dose of 800 mg. Intra-patient dose escalation in this setting might be an option. (Source: Targeted Oncology)
Source: Targeted Oncology - June 5, 2021 Category: Cancer & Oncology Source Type: research

The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
AbstractBackgroundSince a non-negligible fraction of patients with metastatic melanoma does not experience long-term disease control, even with immunotherapy and targeted therapy, new biomarkers for patient stratification and treatment tailoring are needed in this setting.ObjectiveWe investigated the association of a novel immune-inflammatory blood-based biomarker, the Pan-Immune-Inflammation Value (PIV), with clinical outcomes of patients with metastatic melanoma receiving first-line therapy.Patients and MethodsWe retrospectively included patients treated at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan and ...
Source: Targeted Oncology - June 2, 2021 Category: Cancer & Oncology Source Type: research

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
ConclusionsBintrafusp alfa showed signs of clinical efficacy with a manageable safety profile in patients with heavily pretreated, advanced esophageal adenocarcinoma.Clinical Trials RegistrationNCT02517398. (Source: Targeted Oncology)
Source: Targeted Oncology - May 19, 2021 Category: Cancer & Oncology Source Type: research

Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
ConclusionsICI neoadjuvant therapy may be a safe and efficacious treatment option in patients with resectable NSCLC. Combined with chemotherapy, ICI appears to be more efficacious, but displays more adverse events. More ongoing clinical trials will shed further light on the safety and efficacy of ICI neoadjuvant therapy in patients with resectable NSCLC. (Source: Targeted Oncology)
Source: Targeted Oncology - May 13, 2021 Category: Cancer & Oncology Source Type: research

Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study
ConclusionsIn post-marketing surveillance data, VEGFR-TKIs are associated with increased reporting of various CVAEs, including pericardial diseases, particularly non-malignant pericardial effusion, and aortic dissections. Moreover, VEGFR-TKIs differ in their CVAE reporting patterns. Clinicians should be conscious of these findings in the care of VEGFR-TKIs recipients.Graphic AbstractCardiovascular toxicities of VEGFR-TKIs in the FDA adverse events reporting system (FAERS) database. Post-marketing data of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI)-associated cardiovascular toxicities...
Source: Targeted Oncology - May 10, 2021 Category: Cancer & Oncology Source Type: research

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
AbstractBackgroundPreclinical and clinical data indicate that p53 expression might modulate the activity of the epidermal growth factor receptor (EGFR), influencing response/resistance to anti-EGFR monoclonal antibodies. However, the association between p53 status and clinical outcome has not been clarified yet.ObjectiveIn our study, we evaluated the role of p53 expression in patients withRAS/BRAF wild-type metastatic colorectal cancer (mCRC) receiving irinotecan/cetuximab in an exploratory and a validation cohort.Patients and Methodsp53 expression was analysed in patients withRAS/BRAF wild-type mCRC receiving second-line ...
Source: Targeted Oncology - May 10, 2021 Category: Cancer & Oncology Source Type: research

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
ConclusionsDSP-7888 Dosing Emulsion was well tolerated, with no dose-limiting toxicities, in patients with recurrent or advanced malignancies. Higher WT1-specific CTL induction activity was noted with ID compared with SC administration; because of this, the ID route was selected for further evaluation in the clinical program.Trial registrationClinicalTrials.gov identifier: NCT02498665. (Source: Targeted Oncology)
Source: Targeted Oncology - May 3, 2021 Category: Cancer & Oncology Source Type: research

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
ConclusionsThe MTD of savolitinib was 400 mg qd in both cohorts. Data demonstrate an acceptable safety profile for savolitinib alone, or with osimertinib.Trial registration: Clinicaltrials.gov; NCT02143466; 21 May 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - May 3, 2021 Category: Cancer & Oncology Source Type: research

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcS é-Crizotinib Program
ConclusionsLarge-scale screening forMET-amplified esogastric adenocarcinomas is feasible.MET amplification was observed in 5.5% of gastric and 12.8% of esophageal adenocarcinomas. Crizotinib shows encouraging results in selected patients. Thus, c-MET inhibition forMET-amplified tumors deserves further evaluation.Trial Registration NumberNCT02034981.Date of Registration14 January 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - May 1, 2021 Category: Cancer & Oncology Source Type: research

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
ConclusionsAlthough the hazard ratio for overall survival suggested a higher risk of death for patients withNTRK gene fusions, the difference was not statistically significant. Co-occurrence ofNTRK gene fusions and other actionable biomarkers was uncommon. (Source: Targeted Oncology)
Source: Targeted Oncology - April 24, 2021 Category: Cancer & Oncology Source Type: research

Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy
ConclusionsProgression-free survival may be enhanced by the use of targeted therapy with concurrent radiotherapy, use of multimodal therapy, and use of newer targeted therapy. Future clinical trials should consider use of concurrent radiotherapy and multimodal therapy for patients with advanced chordoma. (Source: Targeted Oncology)
Source: Targeted Oncology - April 24, 2021 Category: Cancer & Oncology Source Type: research

The Activity of Crizotinib in Chemo-Refractory MET -Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcS é-Crizotinib Program
ConclusionsLarge-scale screening forMET-amplified esogastric adenocarcinomas is feasible.MET amplification was observed in 5.5% of gastric and 12.8% of esophageal adenocarcinomas. Crizotinib shows encouraging results in selected patients. Thus, c-MET inhibition forMET-amplified tumors deserves further evaluation.Trial Registration NumberNCT02034981.Date of Registration14 January 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2021 Category: Cancer & Oncology Source Type: research

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
ConclusionsBintrafusp alfa demonstrated a manageable safety profile and efficacy in Asian patients with pretreated esophageal SCC.Clinical Trials RegistrationNCT02699515. (Source: Targeted Oncology)
Source: Targeted Oncology - April 11, 2021 Category: Cancer & Oncology Source Type: research

Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
ConclusionsThese real-world data complement the findings from randomized controlled trials, indicating that first- and second-line AAP is well tolerated and effective in patients with mCRPC, including those with underlying CV comorbidities.Trial Registration NumberNCT02236637, registered 8 September 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - April 7, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
A correction to this paper has been published: https://doi.org/10.1007/s11523-021-00812-7 (Source: Targeted Oncology)
Source: Targeted Oncology - March 31, 2021 Category: Cancer & Oncology Source Type: research

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
AbstractLiquid biopsy recently gained widespread attention as a noninvasive alternative/complementary technique to tissue biopsy in patients with cancer. As technological advances have improved both feasibility and turnaround time, liquid biopsy has expanded tumor molecular analysis with acknowledgement of both spatial and temporal heterogeneity, overcoming many limitations of traditional tissue biopsy. Because of its diagnostic, prognostic, and predictive value, liquid biopsy has been extensively studied also in metastatic colorectal cancer. Indeed, as personalized medicine establishes its role in cancer treatment, geneti...
Source: Targeted Oncology - March 18, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Sequential Treatment of Sorafenib –Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
A correction to this paper has been published: https://doi.org/10.1007/s11523-021-00808-3 (Source: Targeted Oncology)
Source: Targeted Oncology - March 18, 2021 Category: Cancer & Oncology Source Type: research

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
AbstractLoss-of-function mutations inBRCA1 andBRCA2 are detected in at least 5% of unselected patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for DNA homologous recombination repair (HRR). This review provides an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of BC. Olaparib and talazoparib are PARP inhibitors approved as monotherapies for deleterious/suspected deleterious germline BRCA-mutated, HER2-negative BC. Olaparib is approved in the USA for metastatic BC and in Europe for locally advanced/metastatic BC. Talazoparib is approved for locally adva...
Source: Targeted Oncology - March 12, 2021 Category: Cancer & Oncology Source Type: research

Coming of Age of Immunotherapy of Urothelial Cancer
AbstractFollowing platinum-based regimens becoming the reference standard of care, it has taken almost four decades to find a systemic treatment that improved overall survival in metastatic urothelial tumors. Single-agent immune checkpoint inhibitors have not only improved overall survival but also the quality of life of patients with metastatic urothelial tumors after failure of platinum-based regimens and as a maintenance therapy after four to six cycles of standard first-line chemotherapy. In addition, very promising data are emerging when single-agent immunotherapy is offered as adjuvant or neoadjuvant treatment for pa...
Source: Targeted Oncology - March 12, 2021 Category: Cancer & Oncology Source Type: research

Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer
ConclusionsOur findings suggest that177Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph node metastatic castration-resistant prostate cancer, and in individuals with chemotherapy-na ïve status and lower levels of baseline PSA. (Source: Targeted Oncology)
Source: Targeted Oncology - March 9, 2021 Category: Cancer & Oncology Source Type: research

Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
AbstractDysregulation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin signaling is common in both indolent and aggressive forms of malignant lymphoma, for which several targeted therapies have been developed. Copanlisib is a highly selective and potent intravenous pan-class I PI3K inhibitor that has demonstrated durable objective responses and a manageable safety profile in heavily pre-treated patients with indolent lymphomas. As a result, copanlisib monotherapy received accelerated approval from the US Food and Drug Administration for the treatment of adults with relapsed follicular ...
Source: Targeted Oncology - March 9, 2021 Category: Cancer & Oncology Source Type: research

Sequential Treatment of Sorafenib –Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
ConclusionThis study provides additional proof of the superiority of the S –R treatment over the S–P treatment approach in advanced HCC patients from a real-life setting. (Source: Targeted Oncology)
Source: Targeted Oncology - March 1, 2021 Category: Cancer & Oncology Source Type: research

Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison
ConclusionsThe present MAIC highlights that the combination of atezolizumab plus bevacizumab is superior to lenvatinib. However, updated data or sub-analyses of the IMbrave150 trial would provide more robust estimates for such a treatment comparison. (Source: Targeted Oncology)
Source: Targeted Oncology - February 27, 2021 Category: Cancer & Oncology Source Type: research

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR -Mutated NSCLC
ConclusionsPre-treatmentEGFR copy number gain determined by amplicon-based next generation sequencing data predicts worse overall survival inEGFR-mutated patients treated with first-line EGFR-tyrosine kinase inhibitors. T790M at relapse and subsequent treatment with osimertinib predict longer overall survival. (Source: Targeted Oncology)
Source: Targeted Oncology - February 19, 2021 Category: Cancer & Oncology Source Type: research

BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
AbstractBackgroundB-Raf proto-oncogene (BRAF)-V600E mutations (BRAFmt) in colorectal cancer (CRC) predominantly occur in right-side (RS) primaries. In metastatic CRC (mCRC), there is substantial overlap between the reported features of BRAFmt and of an RS primary.ObjectivesTo explore the significance of BRAFmt in a left-side (LS) primary, we analysed data from a multi-site mCRC registry. Tumours distal to the splenic flexure were considered LS.ResultsOf 3380 patients enrolled from June 2009 to June 2020, 214 (13%) of 1657 with known status were BRAFmt: 127 (24%) of 524 RS and 87 (8%) of 1133 LS. LS versus RS BRAFmt were yo...
Source: Targeted Oncology - February 18, 2021 Category: Cancer & Oncology Source Type: research

Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis
ConclusionsFor patients with EGFR-mutant NSCLC with LM, CSF supernatant is a valuable source for EGFR mutation testing and may provide important information. (Source: Targeted Oncology)
Source: Targeted Oncology - February 10, 2021 Category: Cancer & Oncology Source Type: research

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
This study investigated the ability of lactate dehydrogenase (LDH) and S100 calcium-binding protein B (S100B) to detect response and disease progression during treatment with BRAFi.Patients and MethodsBaseline levels of LDH and S100B and repeated measurements during therapy were recorded retrospectively in 191 patients with metastatic melanoma. LDH and S100B levels were compared between distinct time points (baseline, first follow-up visit [FV], best objective response [BR], and progressive disease [PD]). The prognostic ability of the serum biomarkers in relation to disease-specific survival (DSS) was assessed with univari...
Source: Targeted Oncology - February 8, 2021 Category: Cancer & Oncology Source Type: research

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
ConclusionsFirst-line osimertinib treatment resulted in a clinically meaningful PFS and OS benefit versus comparator EGFR TKI in Chinese patients with EGFRm advanced NSCLC. Safety data were consistent with the known safety profile of osimertinib.Clinical Trial RegistrationClinicalTrials.gov NCT02296125, registered 20 November 2014 (Source: Targeted Oncology)
Source: Targeted Oncology - February 5, 2021 Category: Cancer & Oncology Source Type: research

The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma
AbstractHepatocellular carcinoma (HCC) is one of the most common cancers and a main cause of cancer-associated death worldwide. Even with the successful launch of sorafenib for the clinical treatment of HCC in 2007, the long-term survival for patients with HCC is still suboptimal, largely due to the occurrence of primary or acquired drug resistance. With an improved understanding of the molecular pathophysiology and tumor heterogeneity of HCC, therapeutic options have been evolving rapidly in recent years. While lenvatinib, cabozantinib, regorafenib, and the monoclonal antibody ramucirumab, as well as the immune checkpoint...
Source: Targeted Oncology - February 2, 2021 Category: Cancer & Oncology Source Type: research

Vaccine Therapies for Cancer: Then and Now
AbstractThere are strong biologic and preclinical rationales for the development of therapeutic cancer vaccines; however, the clinical translation of this treatment strategy has been challenging. It is now understood that many previous clinical trials of cancer vaccines used target antigens or vaccine designs that inherently lacked sufficient immunogenicity to induce clinical responses. Despite the historical track record, breakthrough advances in cancer immunobiology and vaccine technologies have supported continued interest in therapeutic cancer vaccinations, with the hope that next-generation vaccine strategies will ena...
Source: Targeted Oncology - January 29, 2021 Category: Cancer & Oncology Source Type: research

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers
ConclusionsAbemaciclib was well tolerated and the safety and PK profiles in Chinese patients were comparable to those previously reported in non-Chinese populations. Preliminary antitumor activity was observed.ClinicalTrials.gov identifierNCT02919696. (Source: Targeted Oncology)
Source: Targeted Oncology - January 25, 2021 Category: Cancer & Oncology Source Type: research

Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
ConclusionsThe development of irAEs might be associated with survival outcomes with nivolumab treatment in patients with  AGC. (Source: Targeted Oncology)
Source: Targeted Oncology - January 21, 2021 Category: Cancer & Oncology Source Type: research

Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
ConclusionsThe combined analysis of these studies confirms the objective tumor responses and improvements in PFS observed in the initial phase III trial, providing further support for the clinical benefit of sunitinib in patients with advanced panNETs.ClinicalTrials.gov IdentifiersNCT00428597 and NCT01525550. (Source: Targeted Oncology)
Source: Targeted Oncology - January 7, 2021 Category: Cancer & Oncology Source Type: research

Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
ConclusionsLifetime smoking exposure plays a significant role in the effectiveness of pembrolizumab in patients with metastatic UC. (Source: Targeted Oncology)
Source: Targeted Oncology - January 5, 2021 Category: Cancer & Oncology Source Type: research

Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers
ConclusionsThe majority of uterine and ovarian cancers (93%) did not have molecular alterations with corresponding Food and Drug Administration-approved treatments. Even in patients with a potentially actionable alteration, gynecologic oncologists were more likely to choose an alternative therapy. Further investigation is warranted to determine which patients with uterine and ovarian cancer are most likely to benefit from molecular tumor profiling and the ideal timing of testing. The potential to identify effective therapeutic options in a minority of patients needs to be balanced with the current limited clinical applicab...
Source: Targeted Oncology - January 5, 2021 Category: Cancer & Oncology Source Type: research

Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
AbstractPROteolysis Targeting Chimeras (PROTACs) are a family of heterobifunctional small molecules that specifically target cellular proteins for degradation. Given that their mode of action is distinct from that of small-molecule inhibitors widely used in clinical practice, PROTACs have the potential to improve current cancer therapies. Multiple studies have suggested that PROTACs exhibit enhanced pharmacodynamics and reduced toxicity both in vitro and in vivo compared to clinically relevant small-molecule kinase inhibitors. In addition, PROTACs have been reported to be less prone to mutation-mediated drug resistance in ...
Source: Targeted Oncology - December 28, 2020 Category: Cancer & Oncology Source Type: research

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
ConclusionsThe maximum tolerated dose of rucaparib is 500 mg twice daily when co-administered with bevacizumab. The plasma concentration –time profiles of rucaparib in combination with bevacizumab suggest no pharmacokinetic interactions between the drugs. The randomized phase II portion of MITO 25 will further investigate rucaparib maintenance treatment with or without bevacizumab in patients with newly diagnosed stage III–IV ova rian cancer who responded to carboplatin-paclitaxel chemotherapy with or without bevacizumab.Trial RegistrationClinicalTrials.gov identifier NCT03462212; registered March 2018. (Source: Targeted Oncology)
Source: Targeted Oncology - December 28, 2020 Category: Cancer & Oncology Source Type: research

Correction to: SB8: A Bevacizumab Biosimilar
The article SB8: A Bevacizumab Biosimilar, written by Yahiya Y. Syed, was originally published (Source: Targeted Oncology)
Source: Targeted Oncology - December 11, 2020 Category: Cancer & Oncology Source Type: research